美国华人生物医药科技协会二月份热点讲座

-大数据在生命科学和医疗健康领域的应用

大数据正在深刻影响各种商业变革，包括生命科学和医疗健康领域。生命科学和医疗健康的数据来源和形式多样，包括基因测序、分子通道、不同的人群等。例如，每个临床试验需要成千上万病患的数年统计资料，而DNA测序的每个样本产生的数据则以兆兆位计算.......如果能高效、高速地利用这些大数据，无疑将为生命科学领域带来无限机遇，但对如何分析利用带来了全新挑战。

如果你想了解更多信息，请带着好奇的心和不解的问题，来听听来自IT，药厂以及FDA的大拿们各自的心得体会，经验分享。同时也是认识同行，扩大专业交际网的绝佳机会。

时间：2月3号（周六）早上9点

地点：9600 Blackwell Rd. Suite 300, Rockville, MD 20850

注：作为最具影响力的华人专业团体之一的CBA主办的系列讲座，宗旨是为生物科学研究领域的专业人士提供关于药物开发和销售许可的更深层次解读的机会，同时促进药物研发产业与政府监管部门的专业人士之间的交流。您的支持将帮助CBA持久发展，亦使每年近一万人次的来访听众从中获益。支持CBA，将对您企业的品牌文化与形象产生潜移默化的积极影响，增加在具有良好的教育背景、对生物科技感兴趣的受众群体中的传播范围和认知度。

愿意赞助的公司商家，我们将为您提供场地用作展示和咨询，也可考虑产品展卖；请联系：李利（Frank） 240-425-7668   workshops@cba-usa.org

CHINESE BIOPHARMACEUTICAL ASSOCIATION, USA

2017-2018 Workshop Series-3

Big Data in Life Sciences and Healthcare

Register Eventbrite or goo.gl/AUpVKf today  to reserve your seat

Join us on February 3 (Saturday 9:00 am- 2:00 pm), 2018 at 9600 Blackwell Rd. Suite 300, Rockville, MD 20850 for an educational workshop on Big Data in Life Sciences and Healthcare. Four distinguished speakers from pharmaceutical industry, consulting firm and regulatory agencies will present the applications and challenges of Big Data, with a focus in Life Sciences & Healthcare. After attending this workshop, you will have a better understanding of the origin, recent progress and future direction of Big Data. Networking opportunities are available after the workshop. Free pizza and water will be served.

Cost: $5.00 for public, but FREE for active members of CBA, and members of CCACC, NIH-CSSA, and ASQ509.

Agenda

Speaker Biosketches (by Alphabet Order)

Roger Ding, Sr. Solutions Consultant, Cloudera

Roger Ding is a Sr. Solutions Consultant at Cloudera, where he joined in 2013 and loves working with big data technologies. He did several presentations on big data technologies in local meetup and taught "Introduction to big data eco-system" class in Montgomery College from 2015 to 2016.He worked as a software engineer for 15 years before joining Cloudera.

Xia Wang, Ph.D., Director, Health Informatics, Global Medicines Development, AstraZeneca

Xia holds a Director position at Health Informatics group within the AstraZeneca clinical development. Xia has records of accomplishment in applying novel informatics solutions and real world data analytics to all phases of medicines development life cycles, spanning diabetes, respiratory and autoimmune therapeutic areas. Currently Xia is leading informatics efforts in AstraZeneca Real World Evidence (RWE) to support clinical and observational studies, medicines comparative effectiveness, payer & pricing strategy and marketing accessing research. Prior to stepping into the clinical domain, Xia was with the AstraZeneca drug discovery in the areas of informatics and computational modeling to support candidate drug identification and optimization. Xia holds a Ph.D. in computational chemistry and has extensive training in broad areas of Informatics.

Wenming Xiao, Ph.D., Principal Investigator, Division of Bioinformatics and Biostatistics, NCTR，FDA

Dr. Xiao had advanced training in biology and computer science in China and United States. He has over 20 years of experience in bioinformatics through his career in industry, academia and government agencies.  Dr. Xiao has numerous publications in peer-reviewed journals such as Nature, PNAS, and N. Engl. J. Med and received NIH Director Award in 2010 in recognition to his contributions to cancer biomarkers discovery. His work in Lymphoma/Leukemia Molecular Profiling resulted in 20 gene biomarkers for Lymphoma Subtyping Test (LST), which is in Phase III global clinical validation trial, and a candidate drug,ibrutinib, which currently is in phase II clinical trial. Dr Xiao currently is a principal investigator in Food and Drug Administration (FDA) and leads an international working group, including 170+ scientists, to establish reference materials, data sets, analysis pipelines, and quality metrics for cancer mutation detection with NGS technology.

Liang Zhao, Ph.D., Director, Division of Quantitative Methods and Modeling (DQMM), Office of Research and Standards, Office of Generic Drugs, CDER, FDA

Dr. Liang Zhao has been serving as Director of DQMM since 2015. He initially joined FDA as a clinical pharmacology reviewer in the Office of Clinical Pharmacology in 2009 and worked as a team leader in the Division of Pharmacometrics in 2013-2015. In the agency, he has covered therapeutic areas of Oncology, Pulmonary, Allergy, and Rheumatology including biosimilar development as clinical pharmacologist, and has later on dedicated to regulatory research and standards for generics. Prior to joining FDA, he worked at MedImmune (the Biotechnology Unit of AstraZeneca) as an Associate Director and was a key contributor to establishing the clinical pharmacology function at the headquarter site. Prior to joining MedImmune, he started his professional career as an Associate Consultant for Strategic Consulting Service, Pharsight and a Research Investigator for Clinical Discovery, Bristol Myers Squibb. He holds a PhD degree in Pharmaceutical Sciences and a master degree in Statistics from the Ohio State University, a master degree in Pharmaceutics from Shanghai Medical University, a bachelor degree in Pharmaceutics from China Pharmaceutical University, and a MBA degree for executives from University of Cambridge.

Co-sponsors

CCACC (Chinese Culture and Community Service Center)

American Society for Quality Section 509 (www.asq509.org) – Washington DC and Maryland Metro - Biomed/Biotech Special-Interest-Group (http://www.asq509.org/ht/d/sp/i/31557/pid/31557)

 NIH-CSSA (Chinese Students and Scholars Association of the National Institutes of Health)